Rezwan Islam
Expertise in
21
conditions

Dr. Rezwan Islam

Hematology Oncology
M Health Fairview Cancer Center Maplewood
1575 Beam Avenue, 
Maplewood, MN 
Accepting New Patients
Offers Telehealth
Expertise in
21
conditions
M Health Fairview Cancer Center Maplewood
1575 Beam Avenue, 
Maplewood, MN 

Overview

Rezwan Islam is a Hematologist Oncology provider practicing medicine in Maplewood, Minnesota.

Dr. Islam is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Pulmonary Embolism, Breast Cancer, and Angiosarcoma.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 6 clinical trials. Dr. Islam is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in WI

Hospital Affiliations

Aspirus Stevens Point Hospital & Clinics, Inc.
Fairview Lakes Health Services
M Health Fairview University Of Mn Medical Center
Aspirus Riverview Hospital & Clinics Inc
M Health Fairview St John's Hospital

Languages Spoken

English
Bengali
Hindi
Urdu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

M Health Fairview Cancer Center Maplewood
1575 Beam Avenue, Maplewood, MN 55109
Other Locations
M Health Fairview Cancer Center Wyoming
5200 Fairview Boulevard, Suite 1300, Wyoming, MN 55092

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Phase: Phase 3
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Other, Drug
Study Drugs: Clobetasol propionate, Regorafenib
Study Phase: Phase 2
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial
Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: September 30, 2019
Intervention Type: Other, Drug, Procedure
Study Phase: Not Applicable
View 5 Less Clinical Trials

4 Total Publications

Clinical Factors Affecting Bevacizumab Efficacy With and Without Conventional Chemotherapy in Metastatic Colon Cancer.
Clinical Factors Affecting Bevacizumab Efficacy With and Without Conventional Chemotherapy in Metastatic Colon Cancer.
Journal: American journal of therapeutics
Published: September 09, 2020
Similar Doctors
Expertise in
29
conditions
Dr. Veronika Bachanova
Hematology Oncology
Expertise in
29
conditions
Dr. Veronika Bachanova
Hematology Oncology
Referral may be required

M Health Fairview Blood And Marrow Transplant Program Minneapolis

909 Fulton Street Southeast, Suite 214, 
Minneapolis, MN 
 (10.5 miles away)
612-676-4200
Languages Spoken:
English, Czech, Russian, Slovak
See accepted insurances
Accepting New Patients
Offers Telehealth

Veronika Bachanova is a Hematologist Oncology provider practicing medicine in Minneapolis, Minnesota. Dr. Bachanova is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bachanova is board certified in Hematology: American Board Of Internal Medicine, 2008. Dr. Bachanova is currently accepting new patients.

Expertise in
25
conditions
Dr. Greg M. Vercellotti
Hematology Oncology | Hematology
Expertise in
25
conditions
Dr. Greg M. Vercellotti
Hematology Oncology | Hematology
Referral may be required

M Health Fairview Blood And Marrow Transplant Program Minneapolis

909 Fulton Street Southeast, Suite 214, 
Minneapolis, MN 
 (10.5 miles away)
612-676-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Greg Vercellotti is a Hematologist Oncology specialist and a Hematologist practicing medicine in Minneapolis, Minnesota. Dr. Vercellotti is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Vercellotti is board certified in Hematology: American Board Of Internal Medicine, 1982 and Internal Medicine: American Board Of Internal Medicine, 1979. Dr. Vercellotti is currently accepting new patients.

Expertise in
78
conditions
Dr. Vladimir Hugec
Hematology Oncology
Expertise in
78
conditions
Dr. Vladimir Hugec
Hematology Oncology
Referral may be required

Minnesota Oncology Hematology PA - Maplewood

1580 Beam Avenue, 
Maplewood, MN 
 (1.1 miles away)
651-779-7978
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vladimir Hugec is a Hematologist Oncology provider practicing medicine in Maplewood, Minnesota. Dr. Hugec is highly rated in 78 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Chronic Familial Neutropenia, Agranulocytosis, Lung Cancer, and Pancreaticoduodenectomy. Dr. Hugec is board certified in American Board Of Internal Medicine,2006 and Medical Oncology. Dr. Hugec is currently accepting new patients.

Frequently Asked Questions about Dr. Rezwan Islam

How do I make an appointment with Dr. Rezwan Islam?

You can book an appointment with Dr. Rezwan Islam by calling their office at 651-232-7970. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rezwan Islam a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rezwan Islam is classified as an Advanced expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rezwan Islam specialize in?

While Dr. Rezwan Islam is a Hematology Oncology, they have specific expertise in Inflammatory Breast Cancer, Pulmonary Embolism, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Rezwan Islam participate in research or clinical trials?

Yes. Dr. Rezwan Islam has published 4 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Dr. Rezwan Islam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rezwan Islam accept my insurance?

Dr. Rezwan Islam accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 651-232-7970 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Islam's expertise for a condition
ConditionClose
      View All 21 Advanced Conditions
      View All 105 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile